-
Calls To Poison Control Centers On The Rise In This State Due To Delta-8 Products
Thursday, January 19, 2023 - 4:24pm | 445Virginia's poison control centers recently revealed how often they deal with calls related to synthetic cannabis products. In 2022, there were more than 1,200 THC-related calls in three poison center districts in the state, according to a news local outlet citing data. Video by 13 News...
-
CDC New Study Shows Pfizer, Moderna COVID-19 Shots 90% Effective Against Infection In Real-World Setting
Monday, March 29, 2021 - 11:49am | 333The two-dose COVID-19 vaccines from Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) lower the risk for infection by up to 90%, according to data released by the U.S. Centers for Disease Control and Prevention...
-
Coronavirus Checklist: What You'll Need To Have At Home In Case Of Quarantine
Thursday, March 12, 2020 - 11:58am | 852Thousands of U.S. citizens are under quarantine due to coronavirus exposure. They include people evacuated from Wuhan, China; passengers of the Diamond Princess cruise ship; and residents of a Washington state nursing home where four people recently died. The Center for Disease...
-
Dollar General Inflates on Earnings
Monday, March 25, 2013 - 10:40am | 470Dollar General (NYSE: DG) has opened the week up considerably on word of a successful fourth quarter. The Goodlettsville, Tennessee-based firm posted fourth quarter earnings of $0.97 per share, up 14 percent year-over-year. This figure easily topped the EPS of $0.90 analysts hoped for. Fourth...
-
Removing Sugar is Good for General Mills' Health
Monday, October 15, 2012 - 3:29pm | 404Could it be that General Mills (NYSE: GIS) and Nestle are taking a page from McDonald's (NYSE: MCD) book when it comes to giving parents and children healthier options at meal time? According to a Reuters report, this could very well be the case as the cereal distributors have vowed to reduce...
-
Bristol-Myers' Trash is Gilead Sciences' Treasure
Friday, August 24, 2012 - 9:16am | 584Amid a track record of continued success and secured patents, Gilead Sciences (NASDAQ: GILD) is once again headlining the infectious disease realm with a new hepatitis C offering despite news that Bristol-Myers Squibb (NYSE: BMY) has discontinued its experimental therapy trials following a patient...